The oncology biomarkers market size has grown rapidly in recent years. It will grow from $17.3 billion in 2025 to $19.73 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to expansion of cancer screening programs, advancements in molecular biology research, increased availability of biomarker testing platforms, growth in oncology clinical trials, rising collaboration between research institutions and hospitals.
The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $33.63 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing demand for personalized oncology therapies, expansion of AI-driven biomarker discovery, growing investments in cancer genomics, rising adoption of liquid biopsy technologies, increased focus on early cancer detection and monitoring. Major trends in the forecast period include increasing adoption of precision oncology diagnostics, rising use of genetic and protein biomarkers, growing integration of bioinformatics in biomarker analysis, expansion of companion diagnostics development, enhanced focus on personalized cancer treatment.
The rising incidence of cancer is expected to drive growth in the oncology biomarker market. Cancer is characterized by the uncontrolled growth of cells that can gradually spread throughout the body. Oncological biomarkers offer insights into cancer type by analyzing genes, proteins, and other biological substances in the patient. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, representing a 77% increase from an estimated 20 million cases in 2022. This rising cancer burden is therefore supporting the expansion of the oncology biomarkers market.
Major companies in the oncology diagnostics market are focusing on developing advanced biomarker-based assays to enhance early cancer detection, monitor minimal residual disease (MRD), and evaluate patient responses to therapy. MRD refers to the small number of cancer cells that may remain after treatment and could cause recurrence if undetected. For example, in May 2024, Tempus, a US-based artificial intelligence and precision medicine company, launched its MRD test portfolio, including the xM test and xM (NeXT Personal Dx) test developed by Personalis. The portfolio features tumor-naïve and tumor-informed assays capable of detecting early cancer recurrence and residual disease, while also monitoring responses to immunotherapy. By leveraging circulating tumor biomarkers, these assays provide clinicians with sensitive, actionable insights to guide patient management.
In May 2023, Freenome, a US-based biotech company, completed the acquisition of Oncimmune Ltd., a UK-based company specializing in developing immunodiagnostics. This strategic acquisition is poised to enhance Freenome's cancer screening efforts by providing additional clinical and commercial resources. Moreover, it will contribute to augmenting Freenome's multi-omics platform, offering a more comprehensive view of the tumor microenvironment.
Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA.
North America was the largest region in the oncology biomarkers market in 2025. The regions covered in the oncology biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the oncology biomarkers market by increasing costs of imported reagents, assay kits, sequencing instruments, imaging systems, and analytical software tools. Diagnostic laboratories and research institutions in North America and Europe are most affected due to dependence on imported high-end technologies, while Asia-Pacific faces cost pressure on biomarker kit exports. These tariffs are increasing testing costs and research budgets. However, they are also encouraging local assay development, regional manufacturing of diagnostic kits, and investment in domestic biomarker research infrastructure.
The oncology biomarkers market research report is one of a series of new reports that provides oncology biomarkers market statistics, including oncology biomarkers industry global market size, regional shares, competitors with a oncology biomarkers market share, detailed oncology biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biomarkers industry. This oncology biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oncology biomarkers are biological indicators, such as genes, proteins, or other molecules, that can indicate the presence of cancer or its progression. They play a crucial role in diagnosing cancer, predicting treatment responses, and monitoring disease progression or recurrence. By analyzing these biomarkers, healthcare providers can create personalized treatment plans tailored to individual patients.
The primary categories of oncology biomarkers include protein biomarkers, genetic biomarkers, and others. Protein biomarkers involve the use of one or multiple proteins for diagnosing diseases, understanding prognosis, and monitoring a patient's biological response to treatment. Profiling technologies encompass omics technologies, imaging technologies, immunoassays, bioinformatics, and others. Cancer types covered by oncology biomarkers include breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, ovarian cancer, liver cancer, and others. These biomarkers find various applications such as diagnostics, research and development, prognostics, risk assessment, and more, predominantly utilized in hospitals, academic and cancer research institutes, ambulatory surgical centers, and diagnostic laboratories.
The oncology biomarkers market consists of sales of epigenetic biomarkers, metabolic biomarkers and proteomic biomarkers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $33.63 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing demand for personalized oncology therapies, expansion of AI-driven biomarker discovery, growing investments in cancer genomics, rising adoption of liquid biopsy technologies, increased focus on early cancer detection and monitoring. Major trends in the forecast period include increasing adoption of precision oncology diagnostics, rising use of genetic and protein biomarkers, growing integration of bioinformatics in biomarker analysis, expansion of companion diagnostics development, enhanced focus on personalized cancer treatment.
The rising incidence of cancer is expected to drive growth in the oncology biomarker market. Cancer is characterized by the uncontrolled growth of cells that can gradually spread throughout the body. Oncological biomarkers offer insights into cancer type by analyzing genes, proteins, and other biological substances in the patient. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, representing a 77% increase from an estimated 20 million cases in 2022. This rising cancer burden is therefore supporting the expansion of the oncology biomarkers market.
Major companies in the oncology diagnostics market are focusing on developing advanced biomarker-based assays to enhance early cancer detection, monitor minimal residual disease (MRD), and evaluate patient responses to therapy. MRD refers to the small number of cancer cells that may remain after treatment and could cause recurrence if undetected. For example, in May 2024, Tempus, a US-based artificial intelligence and precision medicine company, launched its MRD test portfolio, including the xM test and xM (NeXT Personal Dx) test developed by Personalis. The portfolio features tumor-naïve and tumor-informed assays capable of detecting early cancer recurrence and residual disease, while also monitoring responses to immunotherapy. By leveraging circulating tumor biomarkers, these assays provide clinicians with sensitive, actionable insights to guide patient management.
In May 2023, Freenome, a US-based biotech company, completed the acquisition of Oncimmune Ltd., a UK-based company specializing in developing immunodiagnostics. This strategic acquisition is poised to enhance Freenome's cancer screening efforts by providing additional clinical and commercial resources. Moreover, it will contribute to augmenting Freenome's multi-omics platform, offering a more comprehensive view of the tumor microenvironment.
Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA.
North America was the largest region in the oncology biomarkers market in 2025. The regions covered in the oncology biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the oncology biomarkers market by increasing costs of imported reagents, assay kits, sequencing instruments, imaging systems, and analytical software tools. Diagnostic laboratories and research institutions in North America and Europe are most affected due to dependence on imported high-end technologies, while Asia-Pacific faces cost pressure on biomarker kit exports. These tariffs are increasing testing costs and research budgets. However, they are also encouraging local assay development, regional manufacturing of diagnostic kits, and investment in domestic biomarker research infrastructure.
The oncology biomarkers market research report is one of a series of new reports that provides oncology biomarkers market statistics, including oncology biomarkers industry global market size, regional shares, competitors with a oncology biomarkers market share, detailed oncology biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biomarkers industry. This oncology biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oncology biomarkers are biological indicators, such as genes, proteins, or other molecules, that can indicate the presence of cancer or its progression. They play a crucial role in diagnosing cancer, predicting treatment responses, and monitoring disease progression or recurrence. By analyzing these biomarkers, healthcare providers can create personalized treatment plans tailored to individual patients.
The primary categories of oncology biomarkers include protein biomarkers, genetic biomarkers, and others. Protein biomarkers involve the use of one or multiple proteins for diagnosing diseases, understanding prognosis, and monitoring a patient's biological response to treatment. Profiling technologies encompass omics technologies, imaging technologies, immunoassays, bioinformatics, and others. Cancer types covered by oncology biomarkers include breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, ovarian cancer, liver cancer, and others. These biomarkers find various applications such as diagnostics, research and development, prognostics, risk assessment, and more, predominantly utilized in hospitals, academic and cancer research institutes, ambulatory surgical centers, and diagnostic laboratories.
The oncology biomarkers market consists of sales of epigenetic biomarkers, metabolic biomarkers and proteomic biomarkers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Oncology Biomarkers Market Characteristics
3. Oncology Biomarkers Market Supply Chain Analysis
4. Global Oncology Biomarkers Market Trends and Strategies
5. Oncology Biomarkers Market Analysis of End Use Industries
7. Global Oncology Biomarkers Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Oncology Biomarkers Total Addressable Market (TAM) Analysis for the Market
9. Oncology Biomarkers Market Segmentation
10. Oncology Biomarkers Market Regional and Country Analysis
11. Asia-Pacific Oncology Biomarkers Market
12. China Oncology Biomarkers Market
13. India Oncology Biomarkers Market
14. Japan Oncology Biomarkers Market
15. Australia Oncology Biomarkers Market
16. Indonesia Oncology Biomarkers Market
17. South Korea Oncology Biomarkers Market
18. Taiwan Oncology Biomarkers Market
19. South East Asia Oncology Biomarkers Market
20. Western Europe Oncology Biomarkers Market
21. UK Oncology Biomarkers Market
22. Germany Oncology Biomarkers Market
23. France Oncology Biomarkers Market
24. Italy Oncology Biomarkers Market
25. Spain Oncology Biomarkers Market
26. Eastern Europe Oncology Biomarkers Market
27. Russia Oncology Biomarkers Market
28. North America Oncology Biomarkers Market
29. USA Oncology Biomarkers Market
30. Canada Oncology Biomarkers Market
31. South America Oncology Biomarkers Market
32. Brazil Oncology Biomarkers Market
33. Middle East Oncology Biomarkers Market
34. Africa Oncology Biomarkers Market
36. Oncology Biomarkers Market Competitive Landscape and Company Profiles
37. Oncology Biomarkers Market Other Major and Innovative Companies
40. Oncology Biomarkers Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Oncology Biomarkers Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses oncology biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for oncology biomarkers? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology biomarkers market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Biomarker Type: Protein Biomarkers; Genetic Biomarkers; Other Biomarker Types2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Leukemia; Ovarian Cancer; Liver Cancer; Other Cancer Types
3) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
4) By End-User: Hospitals; Academic And Cancer Research Institutes; Diagnostic Laboratories
Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens; Circulating Tumor Cells (CTCs); Enzymatic Biomarkers2) By Genetic Biomarkers: DNA Mutations; Gene Expression Profiles; Single Nucleotide Polymorphisms (SNPs)
3) By Other Biomarker Types: Metabolomic Biomarkers; Epigenetic Biomarkers; MicroRNA Biomarkers
Companies Mentioned: F Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Merck KGaA; Siemens Healthcare GmbH; Becton Dickinson and Company; GE Healthcare Technologies Inc.; Eurofins Scientific SE; Agilent Technologies Inc.; Hologic Inc.; Illumina Inc.; bioMerieux SA; Bio-Rad Laboratories Inc.; Bruker Corporation; QIAGEN NV; Exact Sciences Corporation; Sysmex Corporation; PerkinElmer Inc.; Leica Biosystems; Myriad Genetics Inc.; Guardant Health Inc.; Enzo Biochem Inc.; Biocartis Group NV; Agendia Inc.; Epigenomics AG; OncoDNA SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Oncology Biomarkers market report include:- F Hoffmann-La Roche AG
- Novartis AG
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Merck KGaA
- Siemens Healthcare GmbH
- Becton Dickinson and Company
- GE Healthcare Technologies Inc.
- Eurofins Scientific SE
- Agilent Technologies Inc.
- Hologic Inc.
- Illumina Inc.
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- Bruker Corporation
- QIAGEN NV
- Exact Sciences Corporation
- Sysmex Corporation
- PerkinElmer Inc.
- Leica Biosystems
- Myriad Genetics Inc.
- Guardant Health Inc.
- Enzo Biochem Inc.
- Biocartis Group NV
- Agendia Inc.
- Epigenomics AG
- OncoDNA SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 19.73 Billion |
| Forecasted Market Value ( USD | $ 33.63 Billion |
| Compound Annual Growth Rate | 14.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
